LOW-DOSE FLUPHENAZINE DECANOATE IN MAINTENANCE TREATMENT OF SCHIZOPHRENIA

被引：38

作者：

KANE, JM

RIFKIN, A

QUITKIN, F

NAYAK, D

SARAF, K

RAMOSLORENZI, JR

KLEIN, DF

SACHAR, EJ

机构：

[1] Devdutt Nayak, M.D. and Kishore Saraf, M.D., are Research Psychiatrists and Jorge R. Ramos-Lorenzi, M.D., is Director Aftercare Clinic

[2] Arthur Rifkin, M.D., is Director, Comprehensive Treatment Program, Department of Psychiatry, Mount Sinai Medical Center

[3] Edward J. Sachar, M.D., is Director, New York State Psychiatric Institute and Chairman, Department of Psychiatry, Columbia University College of Physicians and Surgeons

来源：

PSYCHIATRY RESEARCH | 1979年 / 1卷 / 03期

关键词：

decanoate; Fluphenazine; minimal dosage; outcome; schizophrenia;

D O I：

10.1016/0165-1781(79)90016-7

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

To test the clinical efficacy of low dose fluphenazine decanoate (1.25 mg to 5.0 mg biweekly), we carried out two separate experiments: (1) an open trial in 57 schizophrenic outpatients, lasting 6 months; (2) a double-blind, placebo-controlled discontinuation study in a subgroup of patients who maintained good remission throughout the entire 6-month open trial. The results suggest that lower doses of fluphenazine decanoate than those usually used may be effective in preventing psychotic relapse while keeping total cumulative dosage to a minimum. © 1979.

引用

页码：341 / 348

页数：8

共 24 条

[1]

Baldessarini, Tarsy, Mechanisms underlying tardive dyskinesia, The Basal Ganglia, (1976)

[2]

Davis, Overview: Maintenance therapy in psychiatry: I. Schizophrenia, American Journal of Psychiatry, 132, (1975)

[3]

Degwitz, Extrapyramidal motor disorders following long-term treatment with neuroleptic drugs, Psychotropic Drugs and Dysfunction of the Basal Ganglia, (1969)

[4]

Gardos, Cole, The importance of dosage in antipsychotic drug administration: A review of dose response studies, Psychopharmacologia, 29, (1973)

[5]

Gardos, Cole, Maintenance antipsychotic therapy: Is the cure worse than the disease?, American Journal of Psychiatry, 133, (1976)

[6]

Hogarty, Goldberg, Schooler, Ulrich, Drugs and sociotherapy in the aftercare of schizophrenic patients: II. Two-year relapse rate, Archives of General Psychiatry, 31, (1974)

[7]

Hogarty, Ulrich, Mussare, Aristigueta, Drug discontinuation among long-term successfully maintained schizophrenic outpatients, Diseases of the Nervous System, 38, (1977)

[8]

Jus, Pineau, Lachance, Pelchat, Jus, Pires, Villeneuve, Epidemiology of tardive dyskinesia: Part I, Diseases of the Nervous System, 36, (1976)

[9]

Klawans, The pharmacology of tardive dyskinesia, Am J Psychiatry, 130, (1973)

[10]

Leff, Wing, Trial of maintenance therapy in schizophrenics, British Medical Journal, 2, (1971)

← 1 2 3 →